LILRB1 Matched Antibody Pair (693) (APMAB-693LY)

Zeller, T., Münnich, I. A., Windisch, R., Hilger, P., Schewe, D. M., Humpe, A., & Kellner, C. (2023). Perspectives of targeting LILRB1 in innate and adaptive immune checkpoint therapy of cancer. Frontiers in Immunology, 14.

Zou, R., Zhong, X., Liang, K., Zhi, C., Chen, D., Xu, Z., ... & Wang, Y. (2023). Elevated LILRB1 expression predicts poor prognosis and is associated with tumor immune infiltration in patients with glioma. BMC cancer, 23(1), 1-21.

Churchill, H. R., Fuda, F. S., Xu, J., Deng, M., Zhang, C. C., An, Z., ... & Chen, W. (2021). Leukocyte immunoglobulin‐like receptor B1 and B4 (LILRB1 and LILRB4): Highly sensitive and specific markers of acute myeloid leukemia with monocytic differentiation. Cytometry Part B: Clinical Cytometry, 100(4), 476-487.

Wang, Q., Song, H., Cheng, H., Qi, J., Nam, G., Tan, S., ... & Gao, G. F. (2020). Structures of the four Ig-like domain LILRB2 and the four-domain LILRB1 and HLA-G1 complex. Cellular & Molecular Immunology, 17(9), 966-975.

Chen, H., Chen, Y., Deng, M., John, S., Gui, X., Kansagra, A., ... & Zhang, C. C. (2020). Antagonistic anti-LILRB1 monoclonal antibody regulates antitumor functions of natural killer cells. Journal for ImmunoTherapy of Cancer, 8(2).

Harrison, T. E., Mørch, A. M., Felce, J. H., Sakoguchi, A., Reid, A. J., Arase, H., ... & Higgins, M. K. (2020). Structural basis for RIFIN-mediated activation of LILRB1 in malaria. Nature, 587(7833), 309-312.

Zhao, J., Zhong, S., Niu, X., Jiang, J., Zhang, R., & Li, Q. (2019). The MHC class I‐LILRB1 signalling axis as a promising target in cancer therapy. Scandinavian journal of immunology, 90(5), e12804.

Kim, A., Han, C. J., Driver, I., Olow, A., Sewell, A. K., Zhang, Z., ... & Yu, X. (2019). LILRB1 blockade enhances bispecific T cell engager antibody–induced tumor cell killing by effector CD8+ T cells. The Journal of Immunology, 203(4), 1076-1087.

Barkal, A. A., Weiskopf, K., Kao, K. S., Gordon, S. R., Rosental, B., Yiu, Y. Y., ... & Maute, R. L. (2018). Engagement of MHC class I by the inhibitory receptor LILRB1 suppresses macrophages and is a target of cancer immunotherapy. Nature immunology, 19(1), 76-84.

Yu, K., Davidson, C. L., Wójtowicz, A., Lisboa, L., Wang, T., Airo, A. M., ... & Burshtyn, D. N. (2018). LILRB1 polymorphisms influence posttransplant HCMV susceptibility and ligand interactions. The Journal of clinical investigation, 128(4), 1523-1537.

Please try the standard protocols which include: protocols, troubleshooting and guide.

Enzyme-linked Immunosorbent Assay (ELISA)
Flow Cytometry
Immunofluorescence (IF)
Immunohistochemistry (IHC)
Immunoprecipitation (IP)
Western Blot (WB)
Enzyme-Linked Immunospot (ELISpot)
Proteogenomics
Other Protocols

Related Products

Mouse Anti-LILRB1 Recombinant Antibody (3D3-1D12)

Mouse Anti-LILRB1 Recombinant Antibody (CBT4569)

Mouse Anti-LILRB1 Recombinant Antibody (CBYY-I0490)

Mouse Anti-LILRB1 Recombinant Antibody (CBYJL-1676)

Mouse Anti-LILRB1 Recombinant Antibody (4F9)

Mouse Anti-LILRB1 Recombinant Antibody (CBT2316)

Mouse Anti-LILRB1 Recombinant Antibody (CBYY-I0050)

Recombinant Mouse Anti-LILRB1 Recombinant Antibody (VMP55)

Mouse Anti-LILRB1 Recombinant Antibody (CBYY-I0757)

Mouse Anti-LILRB1 Recombinant Antibody (CBYJL-1680)

Isotype control